Helixgate

Helixgate

Uncategorized

Makary’s reported FDA removal could be ‘broad positive’ for biopharma

Published

on

The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head Vinay Prasad highlights the severe turnover rates at the highest rungs of leadership at the health department.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win

Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win

Published

on

Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a​ ​Read More

Continue Reading

Uncategorized

Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls

Published

on

While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed upon with CMOs and prompting the cancellation of an in-house investment.

Continue Reading

Uncategorized

Biotech layoffs are easing, but is the worst over?

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

Read More

Published

on

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

Read More

Continue Reading
Advertisement

Trending